Polyplus, an upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has expanded the LipidBrick Library with several new proprietary cationic lipids for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development. Building forward from LipidBrick IM21.7c and off-the shelf in vivo-jetRNA+transfection reagent, these additional cationic lipids broaden the scope of LNP usage to treat various diseases.
March 31 (Reuters) - Sartorius (SATG.DE) will acquire French lab technology company Polyplus for 2.4 billion euros ($2.62 billion) from private investors to strengthen its activities supplying cell and gene therapy companies.
Polyplus, a solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, introduced a novel cationic lipid for lipid nanoparticle (LNP) formulation in mRNA therapeutic and vaccine development.
Polyplus, an upstream solutions provider for advanced biologic and cell and gene therapy production from research to commercial grade, has confirmed a successful audit and GMP accreditation from the Belgian federal agency for medicines and health product (FAMHP – l’AFMPS l’agence fédérale des medicaments et produits de santé) for GMP grade plasmid DNA production at the Xpress Biologics Milmort facility. The team is now able to scale plasmid DNA production for CGT applications, DNA vaccine development and mRNA synthesis from preclinical development through to GMP commercial manufacturing phases.
Polyplus, a solutions provider for manufacturing of Advanced Therapeutic Medicinal Products from research to commercial grade, has acquired Bio Elpida, a French biotechnology contract development and manufacturing (CDMO) company providing pre-clinical and clinical development services for cell therapy and biologics. The teams will integrate strategically to strengthen the supply chain for GMP formulation and filling at Polyplus.
Polyplus, a leading provider of upstream process solutions for advanced biologic and cell and gene therapy production from research to commercial grade, announced the acquisition of e-Zyvec, a provider of DNA design and production services for tailor-made DNA vectors for gene-therapy, bio-manufacturing and research. Financial details were not disclosed.